journal article·2026-04Open access

Gαi1/3 Is a Novel Regulatory Target for RANKL Signal Transduction and Osteoporosis

Chaowen Bai, Mingchao Zhang, Le Liu, Lide Tao, Chenyang Xu, Hao Chai, Xin Shi, Yin Wang, Xiaopei Zhang, Qiong Chen, Dong Liu, Jinyu Bai, Chang She, Xiaozhong Zhou, Cong Cao, Huajian Shan

Advanced Science· Volume 13· Issue 20

Abstract

ABSTRACT Osteoporosis, characterized by progressive bone loss and increased fracture risk, is a growing concern as the population ages. Current treatments, though advanced, remain limited, underscoring the necessity for novel therapeutic targets. Recent studies have shown that the immune system plays a key role in osteoporosis, with osteoclasts driving bone resorption. Gαi proteins, critical mediators of immune signaling, are implicated in osteoclastogenesis, but their precise role remains unclear. It is demonstrated that Gαi1/3 was highly expressed in osteoclast precursors and mature osteoclasts, with elevated levels in the bone marrow of osteoporotic patients and ovariectomized (OVX) mice. Conditional knockout of Gαi1/3 in osteoclast precursors mitigates OVX‐induced bone loss, improving bone mass and structure. Gαi1/3‐deficient bone marrow monocytes and macrophages exhibit impaired osteoclast formation and reduced bone resorption. In contrast, overexpression of Gαi1/3 enhances osteoclast differentiation and function. In addition, the 173 Asp residue of Gαi3 is identified as crucial for RANK‐TRAF6 binding during RANKL signaling. Inhibition of Gαi1/3 mimics the protective effects of denosumab, a treatment for osteoporosis, in mice. The findings position Gαi1/3 as a critical regulator of osteoclastogenesis and suggest it as a promising therapeutic target for osteoporosis.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Bone Metabolism and Diseases · Bone health and osteoporosis research · Bone health and treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Orthopedics The Second Affiliated Hospital of Soochow University Suzhou China

Department of Endocrinology The Second Affiliated Hospital of Soochow University Suzhou China

Institution of Neuroscience Soochow University Suzhou China

Shanxi Key Laboratory of Rheumatism Immune Microecology The Second Affiliated Hospital of Shanxi Medical University Taiyuan China

Funding

National Natural Science Foundation of China

References (72)

Show source-provided references
1. 10.1016/S0140‐6736(21)02646‐510.1016/S0140‐6736(21)02646‐5 ↗
2. 10.1056/NEJMcp230735310.1056/NEJMcp2307353 ↗
3. 10.1056/NEJMc231462410.1056/NEJMc2314624 ↗
4. 10.1038/s41584‐024‐01120‐w10.1038/s41584‐024‐01120‐w ↗
5. 10.1038/s41577‐019‐0178‐810.1038/s41577‐019‐0178‐8 ↗
6. 10.1016/j.semcdb.2021.05.01410.1016/j.semcdb.2021.05.014 ↗
7. 10.2174/18715281280039273310.2174/187152812800392733 ↗
8. 10.1152/ajpcell.1988.254.5.C68410.1152/ajpcell.1988.254.5.C684 ↗
9. 10.1073/pnas.160950211310.1073/pnas.1609502113 ↗
10. 10.1074/jbc.M10739220010.1074/jbc.M107392200 ↗
11. 10.7150/thno.8074910.7150/thno.80749 ↗
12. 10.1073/pnas.150588711210.1073/pnas.1505887112 ↗
13. 10.1073/pnas.150377911210.1073/pnas.1503779112 ↗
14. 10.1007/s00395-024-01057-x10.1007/s00395-024-01057-x ↗
15. 10.1016/j.pharmthera.2024.10858910.1016/j.pharmthera.2024.108589 ↗
16. 10.1126/science.add894710.1126/science.add8947 ↗
17. 10.1016/j.bcp.2016.04.00510.1016/j.bcp.2016.04.005 ↗
18. 10.1073/pnas.121981011010.1073/pnas.1219810110 ↗
19. 10.1038/jid.2014.32610.1038/jid.2014.326 ↗
20. 10.1073/pnas.172249311510.1073/pnas.1722493115 ↗
21. 10.7150/thno.5638310.7150/thno.56383 ↗
22. 10.7150/thno.6145210.7150/thno.61452 ↗
23. 10.1038/s41419‐023‐06219‐810.1038/s41419‐023‐06219‐8 ↗
24. 10.1038/s41419‐023‐06176‐210.1038/s41419‐023‐06176‐2 ↗
25. 10.7150/thno.2620310.7150/thno.26203 ↗
26. 10.7150/ijbs.8285510.7150/ijbs.82855 ↗
27. Gαi1/3 Mediation of Akt‐mTOR Activation Is Important for RSPO3‐Induced Angiogenesis
28. 10.1126/scisignal.adn455610.1126/scisignal.adn4556 ↗
29. 10.1016/j.pharmthera.2020.10768210.1016/j.pharmthera.2020.107682 ↗
30. 10.1016/j.molmed.2005.11.00710.1016/j.molmed.2005.11.007 ↗
31. 10.1007/s00774‐020‐01191‐110.1007/s00774‐020‐01191‐1 ↗
32. 10.1016/j.jot.2024.05.00110.1016/j.jot.2024.05.001 ↗
33. YME1L Overexpression Exerts Pro‐tumorigenic Activity in Glioma by Promoting Gαi1 Expression and Akt Activation
34. 10.1038/s41413‐024‐00365‐110.1038/s41413‐024‐00365‐1 ↗
35. 10.1002/jbmr.383210.1002/jbmr.3832 ↗
36. 10.1002/advs.20230301510.1002/advs.202303015 ↗
37. 10.1038/boneres.2014.4810.1038/boneres.2014.48 ↗
38. 10.1038/s41592‐019‐0619‐010.1038/s41592‐019‐0619‐0 ↗
39. 10.1001/jamapsychiatry.2023.313810.1001/jamapsychiatry.2023.3138 ↗
40. 10.1038/s42255‐020‐00318‐y10.1038/s42255‐020‐00318‐y ↗
41. 10.1038/s41586‐019‐1104‐810.1038/s41586‐019‐1104‐8 ↗
42. 10.1016/j.stem.2014.06.00810.1016/j.stem.2014.06.008 ↗
43. 10.7150/thno.9290910.7150/thno.92909 ↗
44. 10.1111/acel.1440010.1111/acel.14400 ↗
45. 10.3171/2011.8.SPINE1152110.3171/2011.8.SPINE11521 ↗
46. 10.1016/j.redox.2023.10271110.1016/j.redox.2023.102711 ↗
47. 10.11005/jbm.2014.21.4.23310.11005/jbm.2014.21.4.233 ↗
48. 10.1080/15548627.2022.204843210.1080/15548627.2022.2048432 ↗
49. 10.1016/j.bone.2014.02.00510.1016/j.bone.2014.02.005 ↗
50. 10.1159/00037184510.1159/000371845 ↗
51. 10.1038/s41413‐018‐0040‐910.1038/s41413‐018‐0040‐9 ↗
52. 10.1038/s41584‐023‐00935‐310.1038/s41584‐023‐00935‐3 ↗
53. 10.1002/jbmr.211210.1002/jbmr.2112 ↗
54. 10.1530/JOE‐20‐039010.1530/JOE‐20‐0390 ↗
55. 10.1084/jem.2015008810.1084/jem.20150088 ↗
56. 10.1111/febs.1704910.1111/febs.17049 ↗
57. 10.1074/jbc.M40656120010.1074/jbc.M406561200 ↗
58. 10.1007/s00005‐013‐0230‐510.1007/s00005‐013‐0230‐5 ↗
59. 10.1038/nm159310.1038/nm1593 ↗
60. 10.1007/s00774‐020‐01162‐610.1007/s00774‐020‐01162‐6 ↗
61. 10.1016/S0092‐8674(00)81569‐X10.1016/S0092‐8674(00)81569‐X ↗
62. 10.1038/nature0165810.1038/nature01658 ↗
63. Medical and Public Health Consequences of Nuclear War on the State of Florida
64. 10.1016/j.bone.2023.11675810.1016/j.bone.2023.116758 ↗
65. 10.1152/physiol.00031.202410.1152/physiol.00031.2024 ↗
66. 10.1001/jamanetworkopen.2023.5473410.1001/jamanetworkopen.2023.54734 ↗
67. 10.1016/S2213‐8587(17)30188‐210.1016/S2213‐8587(17)30188‐2 ↗
68. 10.2215/CJN.000000000000021310.2215/CJN.0000000000000213 ↗
69. 10.1001/jama.2023.2823910.1001/jama.2023.28239 ↗
70. 10.1016/j.cellsig.2004.11.00810.1016/j.cellsig.2004.11.008 ↗
71. 10.1007/s43440‐023‐00457‐510.1007/s43440‐023‐00457‐5 ↗
72. 10.1172/JCI12591510.1172/JCI125915 ↗